Group 1 - The company announced the completion of a placement agreement on January 20, 2026, successfully placing a total of 2.1 million shares at a price of HKD 92.85 per share to at least six subscribers [1] - The 2.1 million shares represent approximately 0.70% of the existing issued H shares and about 0.53% of the total issued shares of the company, with the post-placement issued H shares increasing to about 0.69% [1] - The total proceeds from the placement amount to approximately HKD 195 million, with a net amount of about HKD 190 million after deducting placement commissions and related costs, resulting in a net issue price of approximately HKD 90.54 per share [1] Group 2 - The company plans to allocate approximately 60% of the net proceeds, or about HKD 114 million, to fund clinical trials for its core product Tinengotinib in the treatment of cholangiocarcinoma (CCA) and other indications [2] - About 30% of the net proceeds, or approximately HKD 57.04 million, will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [2] - Approximately 10% of the net proceeds, or about HKD 19.01 million, will be allocated for working capital and general corporate purposes [2]

Group 1 - The company completed a placement agreement on January 20, 2026, successfully placing a total of 2.1 million shares at a price of HKD 92.85 per share to at least six subscribers [1] - The 2.1 million shares represent approximately 0.70% of the existing issued H shares and about 0.53% of the total issued shares prior to the placement [1] - The total proceeds from the placement amount to approximately HKD 195 million, with a net amount of about HKD 190 million after deducting commissions and related costs, resulting in a net issue price of approximately HKD 90.54 per share [1] Group 2 - The net proceeds from the placement will be allocated as follows: approximately 60% or HKD 114 million for funding clinical trials of the core product Tinengotinib for cholangiocarcinoma (CCA) and other indications [2] - About 30% or HKD 57.04 million will be used for the development of other products, including TT-00973, TT-01488, and other molecules [2] - Approximately 10% or HKD 19.01 million will be allocated for working capital and general corporate purposes [2]

Core Viewpoint - The stock of药捷安康-B (02617) has experienced a significant decline, dropping over 10% and currently trading at 84.7 HKD, with a trading volume of 117 million HKD. This decline follows the announcement of a share placement at a discount to the market price [1]. Group 1: Share Placement Details - The company announced a placement of 21 million new shares at a price of 92.85 HKD per share, representing a discount of 17.98% compared to the closing price of 113.2 HKD on January 13 [1]. - The net proceeds from the placement are expected to be 190 million HKD [1]. Group 2: Use of Proceeds - Approximately 60% of the proceeds will be allocated to fund clinical trials for the core product Tinengotinib, which is currently undergoing single-agent treatment for cholangiocarcinoma (CCA) in China, as well as research for other indications of the core product [1]. - About 30% of the funds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1]. - The remaining 10% will be utilized for working capital and general corporate purposes [1].

Core Viewpoint - The stock of Zymeworks Inc. (02617) has experienced a decline of over 10%, currently trading at 84.7 HKD, with a transaction volume of 117 million HKD [1] Group 1: Stock Performance - Zymeworks Inc. shares fell by 9.02% to 84.7 HKD as of the latest report [1] - The stock has seen a significant drop following the announcement of a new share placement [1] Group 2: Share Placement Announcement - The company plans to place 21 million new shares at a price of 92.85 HKD per share, representing a discount of 17.98% compared to the closing price of 113.2 HKD on January 13 [1] - The net proceeds from the placement are expected to be 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds will be allocated to clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be utilized for working capital and general corporate purposes [1]

Core Viewpoint - The stock of药捷安康-B (02617) has experienced a significant decline, dropping over 5% and more than 11% in the previous day, indicating market concerns regarding its recent equity placement and pricing strategy [1] Group 1: Stock Performance - As of the latest update, the stock is trading at 95.1 HKD with a trading volume of 82.17 million HKD [1] - The stock has seen a decline of over 5% in the current trading session following a previous drop of more than 11% [1] Group 2: Equity Placement - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] - The expected net proceeds from the placement are around 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds raised will be allocated to clinical trials for the core product Tinengotinib, specifically for its use in treating cholangiocarcinoma (CCA) in China [1] - About 30% of the proceeds will be directed towards the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% is intended for working capital and general corporate purposes [1]

Core Viewpoint - The stock of Zymeworks Inc. (02617) has experienced a significant decline, with a drop of over 5% and a previous plunge of more than 11% [1] Group 1: Stock Performance - As of the latest update, the stock is down 5%, trading at 95.1 HKD, with a trading volume of 82.17 million HKD [1] - The stock has seen a substantial decrease from its closing price of 113.2 HKD on January 13, reflecting a discount of approximately 17.98% on the new share placement price [1] Group 2: Share Placement Details - The company announced a placement of 2.1 million shares, which represents about 0.69% of the enlarged H shares and approximately 0.53% of the total issued shares [1] - The expected net proceeds from the placement are around 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds raised will be allocated to clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be utilized for working capital and general corporate purposes [1]

Group 1 - The core viewpoint of the article is that药捷安康-B (02617) experienced a decline of over 3%, specifically a drop of 3.71%, trading at 109 HKD with a transaction volume of 23.576 million HKD [1] - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] Group 2 - The expected net proceeds from the placement are approximately 190 million HKD, with around 60% allocated for funding clinical trials of the core product Tinengotinib for the treatment of cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% is designated for working capital and general corporate purposes [1]

Core Viewpoint - The company,药捷安康-B (02617), experienced a decline of over 3%, trading at 109 HKD with a transaction volume of 23.576 million HKD following the announcement of a share placement [1] Group 1: Share Placement Details - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] Group 2: Fund Utilization - The expected net proceeds from the placement are approximately 190 million HKD, with around 60% allocated for funding clinical trials of the core product Tinengotinib for the treatment of cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - Approximately 10% of the funds will be directed towards working capital and general corporate purposes [1]

Core Viewpoint - The company,药捷安康, announced a share placement agreement to raise funds for clinical trials and product development, with a significant discount on the share price compared to the market rate [1] Group 1: Share Placement Details - The company entered into a placement agreement with a placement agent to sell 2.1 million shares at a price of HKD 92.85 per share [1] - The placement price represents a discount of approximately 17.98% from the closing price reported on the Hong Kong Stock Exchange on the same day [1] Group 2: Use of Proceeds - The net proceeds from the placement are expected to be approximately HKD 190.14 million [1] - About 60% of the funds will be allocated to clinical trials for the company's core product, Tinengotinib, specifically for its use in treating cholangiocarcinoma (CCA) [1] - Approximately 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be allocated for working capital and general corporate purposes [1]

Core Viewpoint - The company announced a placement agreement to issue 2.1 million shares at a price of HKD 92.85 per share, representing a discount of approximately 17.98% from the closing price of HKD 113.20 on January 13, 2026 [1] Group 1: Placement Details - The placement shares represent about 0.69% of the enlarged issued H shares and approximately 0.53% of the total issued shares after completion [1] - The expected total gross proceeds from the placement are approximately HKD 195 million, with net proceeds estimated at around HKD 190 million [1] - The net issue price is approximately HKD 90.54 per share [1] Group 2: Use of Proceeds - Approximately 60% of the net proceeds will be allocated to fund clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be allocated for working capital and general corporate purposes [1]